亞太藥業(002370.SZ)第三季度預虧4500萬–5500萬元
格隆匯10月14日丨亞太藥業(002370.SZ)公佈,預計2021年前三季度歸屬於上市公司股東的淨虧損9000萬元-10000萬元,上年同期虧損10693.67萬元;扣除非經常性損益後的淨虧損12000萬元–13000萬元,上年同期虧損11847.43萬元;
其中,第三季度歸屬於上市公司股東的淨虧損4500萬元–5500萬元,上年同期虧損5264.98萬元;扣除非經常性損益後的淨虧損3000萬元–4000萬元,上年同期虧損6113.80萬元。
主要系公司本期支付完畢武漢光谷亞太藥業有限公司股權收購價款而相應利息減少,以及公司持有的瑞豐銀行股票產生的公允價值變動收益增加所致;公司扣除非經常性損益後的淨利潤較上年同期減少1.29%-9.73%,主要系本期因集中採購政策推行等致使銷售收入減少所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.